ProShares UltraShort NASDAQ Biotechnology
10 hedge funds and large institutions have $1.34M invested in ProShares UltraShort NASDAQ Biotechnology in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 7 closing their positions.
176% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $548K
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
29% less funds holding
Funds holding: 14 → 10 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
82% less capital invested
Capital invested by funds: $7.39M → $1.34M (-$6.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$439K |
| 2 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
+$226K |
| 3 |
USGIU
U.S. Global Investors (USGI)
San Antonio,
Texas
|
+$66.4K |
| 4 |
Morgan Stanley
New York
|
+$5.57K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$3.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$2.72M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$1.78M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$544K |
| 4 |
Jane Street
New York
|
-$438K |
| 5 |
CT
CMT Trading
Chicago,
Illinois
|
-$385K |
BIS Hedge Fund Activity: Q3 2016 in Review
10 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2016, worth a combined $1.34M — down 82% from $7.39M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIS and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, adding an estimated $439K. The largest seller was Virtu Financial, exiting entirely with an estimated $2.72M sold.
- 10 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2016, down from 14 in Q2 2016.
- Funds reported $1.34M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2016, down 82% quarter-over-quarter.
- 3 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2016 and 7 closed out, a net change of -4 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2016 was Susquehanna International Group, an estimated $439K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2016 was Virtu Financial, an estimated $2.72M sold.
Based on aggregated 13F filings for Q3 2016.